Elite Pharmaceuticals INC /NV/ (ELTP) — SEC Filings

Overview

Elite Pharmaceuticals INC /NV/ (ELTP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: Elite Pharmaceuticals Inc. filed an 8-K on April 2, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an 8-K form, an exhibit (EX-99.1), and associated XBRL data files. No specific financial figures or material events we

Sentiment Summary

Across 26 filings, the sentiment breakdown is: 1 bullish, 24 neutral, 1 mixed. The dominant filing sentiment for Elite Pharmaceuticals INC /NV/ is neutral.

Filing Type Overview

Elite Pharmaceuticals INC /NV/ (ELTP) has filed 17 8-K, 6 10-Q, 1 8-K/A, 2 10-K with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (26)

• Elite Pharmaceuticals Files 8-K — 8-K · Apr 2, 2026 Risk: low
  Elite Pharmaceuticals Inc. filed an 8-K on April 2, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits)
• Elite Pharma Swings to Profit on Soaring Manufacturing Revenue — 10-Q · Nov 14, 2025 Risk: medium
  ELITE PHARMACEUTICALS INC /NV/ reported a significant financial turnaround for the six months ended September 30, 2025, achieving a net income of $7,817,692, a
• Elite Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Nov 12, 2025 Risk: low
  Elite Pharmaceuticals Inc. filed an 8-K/A on November 12, 2025, to amend a previous filing. The amendment pertains to Regulation FD Disclosure and Financial Sta
• Elite Pharmaceuticals Files 8-K — 8-K · Nov 10, 2025 Risk: low
  Elite Pharmaceuticals Inc. filed an 8-K on November 10, 2025, reporting information under Regulation FD and including financial statements and exhibits. The com
• Elite Pharmaceuticals Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on August 14, 2025, reporting on its Results of Operations and Financial Condition. The filing also included Regulation
• Elite Pharma Swings to Loss Despite Revenue Surge on Warrant Revaluation — 10-Q · Aug 14, 2025 Risk: high
  ELITE PHARMACEUTICALS INC /NV/ reported a significant increase in total revenue for the three months ended June 30, 2025, reaching $40,211,097, a substantial ri
• Elite Pharmaceuticals Files 8-K with Financials and Exhibits — 8-K · Aug 8, 2025 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on August 8, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statemen
• 10-K Filing — 10-K · Jun 30, 2025
• Elite Pharmaceuticals Files 8-K — 8-K · Jun 23, 2025 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on June 23, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statement
• Elite Pharmaceuticals Files 8-K — 8-K · Jun 16, 2025 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Elite Pharmaceuticals Files 8-K — 8-K · Apr 30, 2025 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on April 30, 2025, reporting on financial statements and exhibits. The company, incorporated in Nevada with its princip
• Elite Pharmaceuticals Files 8-K — 8-K · Mar 3, 2025 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on March 3, 2025, reporting events as of February 28, 2025. The filing primarily concerns Regulation FD Disclosure and
• Elite Pharmaceuticals Files Q3 2025 10-Q — 10-Q · Feb 13, 2025 Risk: medium
  Elite Pharmaceuticals Inc. reported its third quarter results for the fiscal year ending March 31, 2025. The company's filing covers the period from October 1,
• Elite Pharmaceuticals Files 8-K — 8-K · Dec 26, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on December 26, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The c
• Elite Pharmaceuticals Files 8-K — 8-K · Dec 2, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on December 2, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The co
• Elite Pharmaceuticals Files 8-K — 8-K · Nov 18, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on November 18, 2024, reporting information under Regulation FD and including financial statements and exhibits. The fi
• Elite Pharmaceuticals Files Q2 FY25 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Elite Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal year 2025, ending September 30, 2024. The company's filing details it
• Elite Pharmaceuticals Files 8-K — 8-K · Oct 10, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on October 10, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The fi
• Elite Pharmaceuticals Files 8-K — 8-K · Oct 7, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Elite Pharmaceuticals Files 8-K — 8-K · Aug 27, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on August 27, 2024, reporting on financial statements and exhibits. The company, incorporated in Nevada with its princi
• Elite Pharmaceuticals Files Q1 FY25 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Elite Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the first quarter of fiscal year 2025. The company's principal
• Elite Pharmaceuticals Files 2024 Annual Report — 10-K · Jul 1, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed its annual report for the fiscal year ended March 31, 2024. The company's common stock trades under the symbol ELTP on the OTC
• Elite Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jun 21, 2024 Risk: medium
  Elite Pharmaceuticals, Inc. announced on June 17, 2024, that it entered into a material definitive agreement. The filing does not provide specific details about
• Elite Pharmaceuticals Appoints New Auditor — 8-K · Jun 5, 2024 Risk: low
  Elite Pharmaceuticals, Inc. announced on June 1, 2024, that it has appointed a new independent registered public accounting firm, Citrin Cooperman & Company, LL
• Elite Pharmaceuticals Files 8-K — 8-K · May 20, 2024 Risk: low
  Elite Pharmaceuticals, Inc. filed an 8-K on May 20, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Elite Pharmaceuticals Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 14, 2024 Risk: low
  ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Elite Pharmaceuticals Inc. filed a 10-Q report for the

Risk Profile

Risk Assessment: Of ELTP's 25 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Elite Pharmaceuticals INC /NV/'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $76,532,801
• Net Income: $7,817,692
• EPS: $0.01
• Cash Position: $27,080,586
• Total Assets: $117,247,811

Key Executives

• Chief Executive Officer

Industry Context

The pharmaceutical industry is characterized by high R&D costs, stringent regulatory oversight, and intense competition. Companies often rely on contract manufacturing organizations (CMOs) for specialized production capabilities. Trends include increasing outsourcing of manufacturing to reduce costs and improve efficiency, and a growing demand for specialized drug delivery systems.

Top Tags

8-K (8) · disclosure (8) · financials (7) · pharmaceuticals (5) · regulatory-filing (4) · 10-Q (4) · filing (3) · financial-statements (3) · Pharmaceuticals (2) · Contract Manufacturing (2)

Key Numbers

• Total Revenue: $76.5M — Increased 103% from $37.7M in the prior year period.
• Net Income: $7.8M — Swung from a net loss of $10.4M in the prior year period.
• Manufacturing Fees: $76.0M — Increased 107% from $36.7M in the prior year period, driving revenue growth.
• Gross Profit: $41.3M — Increased 148% from $16.7M in the prior year period.
• Cash and Restricted Cash: $27.1M — Increased 171% from $10.0M in the prior year period.
• Change in fair value of derivative financial instruments - warrants: $14.6M — Expense for the six months ended September 30, 2025, impacting profitability.
• Net Cash Provided by Operating Activities: $19.9M — Increased 332% from $4.6M in the prior year period.
• Total Assets: $117.2M — Increased from $96.4M as of March 31, 2025.
• Total Liabilities: $55.7M — Increased from $42.9M as of March 31, 2025.
• Basic Net Income Per Share: $0.01 — Improved from a loss of $(0.01) per share in the prior year period.
• SEC File Number: 001-15697 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 22-3542636 — Tax identification number for the company.
• Net Loss: $(5.9M) — Compared to $0.6M net income in Q1 2024, primarily due to warrant revaluation
• Derivative Financial Instruments - Warrants Expense: $(22.1M) — Increased from $(2.8M) in Q1 2024, driving the net loss
• Manufacturing Fees Revenue: $39.8M — Increased from $18.4M in Q1 2024, showing strong core business growth

Frequently Asked Questions